Table 1 Distribution of the different pathologies requiring anti-VEGF treatment between the three centers
From: Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice
Number of patients | Center 1 (%) | Center 2 (%) | Center 3 (%) | Overall results (%) |
|---|---|---|---|---|
nAMD | 674 (86.6) | 269 (66.1) | 81 (54) | 1024 (76.7) |
DME | 17 (2.2) | 98 (24.1) | 52 (34.7) | 167 (12.5) |
Vein occlusions | 44 (5.7) | 26 (6.4) | 11 (7.3) | 81 (6.1) |
CNV in high myopic eyes | 22 (2.8) | 3 (0.7) | 6 (4) | 31 (2.3) |
Others | 21 (2.7) | 11 (2.7) | 0 | 33 (2.4) |
Total | 778 (58.3) | 407 (30.5) | 150 (11.2) | 1335 (100) |